FIGURE 1




FIGURE 2





FIGURE 3A



Each Q — L2P =




FIGURE 3B










General structure	DAR	L1-B' (NH_2-L1-B' can be chosen from Table 7)	
		L1	B'
	2	Peptides	-N_3
			
			
			
			
	4		
			

FIGURE 4A



Each Q =




FIGURE 4B








General structure	group	n	L1
	A	2	
	B	3	
	C	4	
	D	6	
	E		

FIGURE 5



Ab-Qtag
I
[MTG]
Ab-N3 tag
A
Linear Linker-Dxd
[click chemistry]
4DAR ADCs
B
Branched Linker-Dxd
[click chemistry]
8DAR ADCs (r = 2)
12DAR ADCs (r = 3)
III
[MTG]
Ab-Branched N3 tag
C
Linear Linker-Dxd
[click chemistry]
8DAR ADCs
D
Branched Linker-Dxd
[click chemistry]
16DAR ADCs (r = 2)
24DAR ADCs (r = 3)
III
E
amino-linker-payloads
[MTG]
4DAR ADCs
or
8DAR ADCs (r = 2)
12DAR ADCs (r =3)

FIGURE 6



Ab-Qtag
[MTG]
Ab-N3 tag
A
Linear Linker-Dad
[click chemistry]
2DAR ADCs
B
Branched Linker-Dad
[click chemistry]
4DAR ADCs (r = 2)
8DAR ADCs (r = 3)
[MTG]
Ab-Branched N3 tag
C
Linear Linker-Dad
[click chemistry]
4DAR ADCs
D
Branched Linker-Dad
[click chemistry]
8DAR ADCs (r = 2)
12DAR ADCs (r = 3)
E
amino-linker-payloads
[MTG]
2DAR ADCs
or
4DAR ADCs (r = 2)
8DAR ADCs (r = 3)

FIGURE 7A




FIGURE 7B




FIGURE 7C



Amine-Linear-Linker-Payload
mTG
Ab-Q295/297
4DAR Ab-(-Linker-Payload)4
Amine-Branched-Linker-Payload
mTG
8DAR Ab-(Branched-Linker-Payload)4

FIGURE 8A



SNU-16, FGFR2-amplified gastric cancer
Tumor volume (mm³)
1500
1200
900
600
300
0
0 5 10 15 20 25 30 35
Days after treatment
FGFR2b-2-BL7-LP1 (1 mg/kg)
FGFR2b-2-BL7-LP1 (3 mg/kg)
FGFR2b-2-BL7-LP1 (10 mg/kg)
FGFR2b-1-BL7-LP1 (1 mg/kg)
FGFR2b-1-BL7-LP1 (3 mg/kg)
FGFR2b-1-BL7-LP1 (10 mg/kg)
Control-BL7-LP1 (10 mg/kg)
Vehicle control

FIGURE 8B



SNU-16 tumor bearing mice
Body weight change (%)
110
105
100
95
0
5
10
15
20
25
30
35
Days after treatment
FGFR2b-2-BL7-LP1 (1 mg/kg)
FGFR2b-2-BL7-LP1 (3 mg/kg)
FGFR2b-2-BL7-LP1 (10 mg/kg)
FGFR2b-1-BL7-LP1 (1 mg/kg)
FGFR2b-1-BL7-LP1 (3 mg/kg)
FGFR2b-1-BL7-LP1 (10 mg/kg)
Control-BL7-LP1 (10 mg/kg)
Vehicle control

FIGURE 9A



SNU16, FGFR2-amplified gastric cancer
Tumor volume (mm3)
1200
900
600
300
0
Dosed on days 0, 7
0
10
20
30
40
Days after treatment
FGFR2b-1-AL1-LP1 (0.3 mg/kg)
FGFR2b-1-AL1-LP1 (1 mg/kg)
FGFR2b-1-AL1-LP1 (3 mg/kg)
Control-AL1-LP1 (3 mg/kg)

FIGURE 9B




SNU-16 tumor bearing mice
Body weight change (%)
110
105
100
95
Dosed on days 0, 7
0
10
20
30
40
Days after treatment
FGFR2b-1-AL1-LP1 (0.3 mg/kg)
FGFR2b-1-AL1-LP1 (1 mg/kg)
FGFR2b-1-AL1-LP1 (3 mg/kg)
Control-AL1-LP1 (3 mg/kg)

FIGURE 10


D2
D1
H4H13290P2
H4H13291P2
H4H13295P2
H4H13300P2
H4H13299P2
H4H13301P2
H4H13302P2
H4H13306P2
H4H13309P2
H4H13311P2
H4H13312P2
H4H13313P2
H4H13316P2
H4H13318P2
H4H13319P2
H4H13325P2
H4H13331P2
H4H13290P2
H4H13291P2
H4H13295P2
H4H13300P2
H4H13299P2
H4H13301P2
H4H13302P2
H4H13306P2
H4H13309P2
H4H13311P2
H4H13312P2
H4H13313P2
H4H13316P2
H4H13318P2
H4H13319P2
H4H13325P2
H4H13331P2